Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 3/20 | 1.00 |
| ▸ | F3 | P13726 | 3/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 1.00 |
| ▸ | F10 | P00742 | 2/20 | 1.00 |
| ▸ | C1R | P00736 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913427 | 0.84 | F7 (0.72) | F7F3F2F10C1R | |
| SCHEMBL786146 | 0.82 | F7 (0.70) | F7F3F2F10C1R | |
| SCHEMBL7394469 | 0.81 | F7 (0.68) | F7F3F2F10C1R | |
| SCHEMBL9646773 | 0.79 | KDM4E (1.00) | F7F3F2F10C1R | |
| SCHEMBL915734 | 0.79 | C1R (1.00) | F7F3F2F10C1R | |
| SCHEMBL30884604 | 0.79 | C1R (1.00) | F7F3F2F10C1R | |
| SCHEMBL14571456 | 0.79 | F2 (0.65) | F7F3F2F10KDM4E | |
| Iodide SCHEMBL11648817 | 0.78 | KDM4E (0.97) | F7F3F2F10C1R | |
| Iodide SCHEMBL11648822 | 0.78 | KDM4E (0.97) | F7F3F2F10C1R | |
| SCHEMBL6031415 | 0.77 | F7 (0.63) | F7F3F2F10C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000030646-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 2000-06-02 | — | — | WO | claimed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| EP-3174602-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016728-A2 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| WO-2000030646-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | F7 2335/4885F3 415/4885F2 2191/4885 |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | F7 3152/4885F3 1856/4885F2 485/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | F7 2356/4885F3 399/4885F2 2192/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | F7 2356/4885F3 399/4885F2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.